Norcross, GA, US and London, UK – March 29th 2012 – AKESOgen, the genomics and biorepository services company, and London Genetics International, an expert in the use of pharmacogenetics in drug discovery and development, today announced a strategic alliance to offer the biopharmaceutical industry innovative pharmacogenetics solutions to advance personalized medicine and provide trans Atlantic services. The alliance combines world-class expertise and American-European infrastructure to support biopharma drug development. Financial terms were not disclosed.
“Our expertise in pharmacogenetic strategy development combined with a professional genomics services company that operates to CLIA standards will make this strategic alliance beneficial to both companies as it will increase our scope of possible services into the Americas with highly qualified and service oriented scientists. This represents our first deal following our acquisition by LSBC which from our side was a critical step for making this happen” said Elizabeth Foot, VP Personalised Medicine and Nutrition, London Genetics International.
Under the alliance, AKESOgen and London Genetics International will collaborate to help biopharma companies take advantage of pharmacogenetic solutions, including novel biomarker and assay development services. By providing biopharma companies strategic advice on the application of pharmacogenetics and innovative pharmacogenetics solutions, AKESOgen and London Genetics can help customers access additional resources and speed the delivery of targeted treatments.